• Skip to primary navigation
  • Skip to main content

Walter Gefrom

Project Manager in Civil Engineering

  • Home
  • Civil Engineering
  • Car Enthusiast
  • Volunteering & Nonprofits
  • Contact
  • Blog

Generic Version of Natalizumab in the Works

July 20, 2022 by Walter Gefrom Leave a Comment

Natalizumab, more popularly known as its brand name, Tysabri, is a Disease Modifying Therapy (DMT) that treats relapsing forms of Multiple Sclerosis through a monthly intravenous dosage. Walter Gefrom discusses the new generic version that is being proposed: 

Walter Gefrom Tysabri

Tysabri, or Natalizumab, is the leading and arguably most effective Disease Modifying Therapy (DMT) for patients with relapsinig forms of MS, including Clinically Isolated Syndrome (CIS), Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS) and Crohn’s disease.  The DMT has been revered by many patients and neurologists, who have witnessed firsthand how effective this medication can be.  However, Tysabri is also one of the most expensive MS DMTs, with its manufacturer Biogen cornering the market on its production.  But that may now change thanks to a biosimilar version of Natalizumab which has just been accepted by the US FDA and EMA.  Walter Gefrom, MS Awareness Advocate, is hopeful that this will put the pressure on Biogen to decrease the cost of Tysabri.  Unfortunately, it is the high price tag of this medication that often keeps patients from receiving its benefits. 

Filed Under: Multiple Sclerosis Tagged With: Advocate, Biogen, Crohen's Disease, MS awareness, Natalizumab, Tysabri, Walter Gefrom

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Home
  • Civil Engineering
  • Car Enthusiast
  • Volunteering & Nonprofits
  • Contact
  • Blog

Copyright © 2023 · Walter Gefrom · All Rights Reserved · Log in